NCT04868604 - 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 11, 2021

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions

Prostatic Neoplasms, Castration-Resistant

Interventions

DRUG

64Cu-SAR-bisPSMA

DRUG

67Cu-SAR-bisPSMA

Trial Locations (6)

NOT_YET_RECRUITING

St Vincent's Public Hospital, Darlinghurst

RECRUITING

Weill Cornell Medicine at New York-Presbyterian, New York

RECRUITING

Mayo Clinic, Rochester

RECRUITING

Washington University School of Medicine at Barnes-Jewish Hospital, St Louis

RECRUITING

GU Research Network, Omaha

RECRUITING

Stanford Cancer Institute, Stanford